Details

Autor(en) / Beteiligte

• Zanwar, Saurabh
• Sidana, Surbhi
• Shune, Leyla
• Puglianini, Omar Castaneda
• Pasvolsky, Oren
• Gonzalez, Rebecca
• Dima, Danai
• Afrough, Aimaz
• Kaur, Gurbakhash
• Davis, James A
• Herr, Megan
• Hashmi, Hamza
• Forsberg, Peter
• Sborov, Douglas
• Anderson Jr, Larry D
• McGuirk, Joseph P
• Wagner, Charlotte
• Lieberman-Cribbin, Alex
• Rossi, Adriana
• Freeman, Ciara L
• Locke, Frederick L
• Richard, Shambavi
• Khouri, Jack
• Lin, Yi
• Patel, Krina K
• Kumar, Shaji K
• Hansen, Doris K

Titel

Impact of extramedullary multiple myeloma on outcomes with idecabtagene vicleucel

Ist Teil von

• Journal of hematology and oncology, 2024-06, Vol.17 (1), p.1-11, Article 42

Ort / Verlag

London: BioMed Central Ltd

Erscheinungsjahr

2024

Link zum Volltext

Quelle

SpringerLink Journals - AutoHoldings

Beschreibungen/Notizen

• Idecabtagene vicleucel (Ide-cel) has demonstrated excellent efficacy and durable responses in patients with relapsed/refractory multiple myeloma (RRMM). However, the outcomes with ide-cel in patients with extramedullary disease (EMD) remain incompletely characterized. We included patients with RRMM treated with ide-cel between May 2021 and April 2023 across 11 US academic institutions. Visceral or soft tissue lesions non-contiguous from bone was classified as EMD. Time-to-event analyses were performed from date of ide-cel infusion. Among 351 patients, 84 (24%) had EMD prior to infusion. The median follow-up from ide-cel infusion was 18.2 months (95% CI: 17-19.3). The day 90 overall response rates (ORR) were 52% vs. 82% for the EMD and non-EMD cohorts, respectively (p < 0.001). The median progression-free survival (PFS) was 5.3 months (95% CI: 4.1-6.9) for the EMD cohort vs. 11.1 months (95% CI: 9.2-12.6; p < 0.0001) for the non-EMD cohort. In a multivariable analysis, EMD was an independent predictor of inferior PFS [hazard ratio 1.5 (1.1-2.2), p = 0.02]. The median overall survival was 14.8 months [95% CI: 9-Not reached (NR)] vs. 26.9 months (26.3 vs. NR, p = 0.006) for the EMD and non-EMD cohorts, respectively. Extramedullary disease represents an independent predictor of inferior day 90 ORR and PFS among patients treated with ide-cel. Keywords: BCMA CAR-T, Ide-cel, Relapsed/refractory myeloma, Radiation, Immunotherapy